Innospec Inc (IOSP) Fair Value & Analysis
Basic Materials · US · Market cap $2.0B
Innospec Inc
IOSP · US
Fair value as of: Jul 15, 2026
From 26 valuation models · updated 25 days ago
Fair value updated Jul 15, 2026, revised from $73.37 to $80.21 (+9.3%) since Jun 24, 2026. Share price +14.4% over the past month.
A solid business, but screening 13% overvalued on our models.
What matters now
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($54.03 to $100.59) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
60‑month range $65.12 – $126.25 · fair‑value band $54.03 – $100.59 · the $92.44 price screens above the $80.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.
Analysis
Innospec Inc (IOSP) currently trades at $92.44, while our model-based Fair Value estimate is $80.21, implying the stock looks roughly 13.2% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Innospec Inc generated revenue of $1.8B at a net margin of 6.4%. Revenue grew 2.8% year over year. It earns a return on equity of 8.7%. The balance sheet holds a net cash position of $240M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $54.03 (bear case) to $100.59 (bull case); at $92.44, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 43% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -13%, IOSP screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Multiples ($80.48) versus Dividend Discount ($24.04). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 67
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company operates through three segments: Performance Chemicals, Fuel Specialties, and Oilfield Services.
Full company description
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company operates through three segments: Performance Chemicals, Fuel Specialties, and Oilfield Services. It offers specialty chemical products used as additives in diesel, jet, marine, fuel oil, and other fuels used in the operation of commercial trucking, marine and aviation engines, power station generators, heating oil, and other industrial machinery applications. It also provides technology-based solutions for customers' processes or products in personal care, home care, agrochemical, construction, mining, and other industrial markets. In addition, the company develops and markets chemical solutions for drilling, completion, production, drag reducing agents, and oil and gas applications. It serves large multinational companies, manufacturers of personal and home care products and global mining, agriculture and building products, and other industrial companies; national and multinational oil companies, fuel marketers and retailers, fuel terminals, marine lines, coating and plastics producers, and other heavy industrial end-users; and multinational public, independent exploration and production, and oilfield services companies. The company was formerly known as Octel Corp. and changed its name to Innospec Inc. in January 2006. Innospec Inc. was founded in 1938 and is headquartered in Englewood, Colorado.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Innospec Inc reported revenue of $1.8B in FY2025 versus $1.5B in FY2021, a compound +4.6%/yr. Reported net income was $117M in FY2025, compounding +5.8%/yr from FY2021.
IOSP screens 13% overvalued. Compare with Linde plc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Analysts Estimate Innospec (IOSP) to Report a Decline in Earnings: What to Look Out for
- IOSP vs. APD: Which Stock Is the Better Value Option?
- IOSP or AIQUY: Which Is the Better Value Stock Right Now?
- Innospec Schedules Second Quarter 2026 Earnings Release and Conference Call
Peer Group
Specialty Chemicals · 676 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $489.98 | $222.03 | -55% |
| Nan Ya Plastics Corporation 1303 | 181.50 TWD | 255.83 TWD | +41% |
| Wanhua Chemical Group 600309 | ¥70.04 | ¥68.03 | -3% |
| Novozymes A/S NSISB | kr 428.20 | kr 179.66 | -58% |
| Asian Paints Limited ASIANPAINT | ₹2,689 | ₹668.81 | -75% |
| Solar Industries India Limited SOLARINDS | ₹18,236 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,560 | ₹351.84 | -77% |
| PT Chandra Asri Pacific Tbk TPIA | 1,805 IDR | 2,888 IDR | +60% |
| Linde India Limited LINDEINDIA | ₹7,115 | ₹757.93 | -89% |
| Berger Paints India Limited BERGEPAINT | ₹493.70 | ₹164.29 | -67% |
Compare Innospec Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Innospec Inc (IOSP) overvalued or undervalued?
What is the fair value of IOSP?
What is the quality score of IOSP?
What is the revenue of Innospec Inc (IOSP)?
What is the net profit margin of IOSP?
Does Innospec Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Innospec Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.